Method of treating periodontal diseases

FIELD: medicine.

SUBSTANCE: implementing the presented method involves mixing gel Hyaludent 1 ml on a slide with Betaleukin 0.0005 ml dissolved in water for injections 1 ml; the produced content is applied with a single application syringe on a desalivated treated area of the involved periodontal tissues and left until completely absorbed for 1-3 minutes; the involved area is exposed to laser light generated by the laser semiconductor dental therapeutic apparatus Optodan with a periodontal tip in the mode II, with the exposure length for 3-5 minutes; the therapeutic course is 8 days daily.

EFFECT: using the method enables achieving the fast regeneration length, ensuring the intact periodontal state in the most patients.

4 tbl, 3 ex

 

The invention relates to medicine, namely to dentistry, and can be used for the treatment of periodontal disease.

From the practice of medicine known method of treatment of periodontal diseases with the use of the drug "betalain, including installations in periodontal pockets under the scheme 5 treatments every other day with an exposure of 15 minutes. The solution is prepared as follows: the contents of 1 vial diluted in 1 ml of sterile 0.9% saline. (Safonova, T. A. Clinical and immunological study of the effectiveness of the drug "betalain" in complex treatment of periodontitis: author. dis. Cand. honey. Sciences / T. A. Safonova. Ekaterinburg, 2010, 24 p.).

The disadvantages of this analogue are:

- when carrying out installations in periodontal pockets of drug solution, put into the periodontal pockets, quickly washed out of them, thus the permeability and fixation of the drug is reduced to a minimal amount of added volume, which reduces therapeutic effect;

- reduce therapeutic effect of the drug leads to a slow normalization of microcirculation, decrease vascular permeability, respectively long-term preservation of hyperemia and edema of the mucous membrane of the gums;

- the presence of a long period of sohronenyami and edema of the mucous membrane of the gums, leads to sustainable pathogenicity (aggressiveness) of the microflora, thereby reducing the stimulation of General and local factors of immune protection;

- the need for continuous installations tissues complicates the procedure of its application, requires a high flow rate of a therapeutic agent;

- carrying out procedures in a day contributes to the long-term positive effect of normalization of local immunity of the oral cavity to the long term regeneration.

Known closest analogue prototype by application to the mucous membrane of the gums and periodontal pockets pockets "Geladen" No. 2 for 15 minutes once a day; laser therapy apparatus "Optodan" on the upper and lower jaw, within three minutes, the rate depends on the stage of the inflammatory process in periodontal tissues (Bolatova L. H. Treatment of inflammatory periodontal diseases drugs on the basis of hyaluronic acid group Geladen": author. dis. Cand. honey. Sciences /L. F. Bolatova. Stavropol, 2010, 24 p.).

However, the disadvantages of the prototype are:

- use turundae with the use of "Geologist" gel gives the inefficient absorption of medication into periodontal pockets, inefficient absorption of the periodontal pocket drug gives a low therapeutic effect in the treatment of chronic�die of pathological processes with acute exudative phenomena - tissue swelling;

- application turund with "Geladen" gel and laser action are not fully exerts immune-modifying and immunomodulatory effects of local protective mechanisms of periodontal tissue, which contributes to the development of polymicrobial, its long persistence, the reduction of reparative processes and increase the frequency of recurrence of periodontal disease;

- prolongation of regeneration increases the risk of irreversible processes, grow the economic costs that are associated with the search for stronger and more effective medicines;

- when applying turundas medication there is the potential presence of residues of cotton fibers (cotton pockets) that contributes to the maintenance of infectious inflammatory process.

The present invention aims at strengthening protective-adaptive pathogenetic mechanisms of correcting immune abnormalities in periodontal tissues with subsequent achieve rapid timing regeneration for 8 days.

Said technical result is achieved in that 1 ml of Gaudent" gel is mixed on a slide with 0.0005 mg "betalain" dissolved in 1 ml of water for injection, then the contents of the disposable application syringe is applied to isolated from saliva, treated area of affected tissues paro�of once and leave until it is completely absorbed within 1-3 minutes followed by exposure to laser therapy using a semiconductor laser dental therapy device "Optogan with periodontal showerheads, mode II, with the exposition 3-5 minutes, the course of treatment for 8 days every day. The proposed method of treatment of periodontal disease is a highly effective and pathogenetically justified. It allows you to quickly obtain a pronounced therapeutic effect and speed up the healing process (for 3-8 visits), eliminate inflammation (especially when exacerbation), already on day 3 marked decrease swelling and bleeding.

The inventive method is applied "Geladen" gel, acts as a binding substance having a high water-holding capacity of 1 molecule of hyaluronic acid binds 200-300 molecules of water. Due to its physicochemical properties, such as high viscosity, the specific ability to bind water and proteins to form proteoglycan aggregates, hyaluronic acid contributes to numerous functions of connective tissue. Hyaluronic acid affects the permeability of the tissue and the transfer of other drugs. The invaluable role of hyaluronic acid not only as a standalone drug, but also as a means of transferring other therapeutic substances to the damaged tissues as well as their possible controlled release. Hyaluronic acid creates a depot of drug at the site of application and gradually crumbling, you�obojdet medicine, improving its pharmacological profile and preventing the development of possible adverse reactions. The mechanism of action is the binding of 1 ml "Geladen" gel mixed with soluble in 1 ml water for injection "betalain" to 0.0005 mg and transport it into tissues with subsequent slow release of the active substance. The drug "betalain" is a dosage form of recombinant interleukin-1 beta produced by genetic engineering technologies. As the stabilizer medication contains polyvinylpyrrolidone-medical, low molecular weight. The product is a porous mass or powder of white color. Due to the wide range of biological activity of interleukin-1 beta is one of the main mediators of the development of protective reactions of the organism. "Betalain" hemostimulating and has an immunostimulating action. Immunostimulatory effect of the drug is realized by increasing the functional activity of neutrophilic granulocytes, induction of differentiation of the precursors of immune cells, enhance the proliferation of lymphocytes, activation of cytokine production and increase of antibody production. The main indication for the use of "betalain" as an immunostimulant are secondary immunodeficiency States, developing p�after heavy injuries, extensive surgery, resulting in septic and purulent-destructive processes, and chronic septic conditions. After applying the gel form "betalain" conduct laser therapy using the apparatus of semiconductor laser therapeutic dental (AALST-01) "Optodan with periodontal attachment, which are anti-inflammatory, normalizes microcirculation vessels and reparative processes in tissues, normalizes blood rheology and is not accompanied by allergic reactions. Laser rays inherent bactericidal and bacteriostatic effect, which is particularly valuable from a position of unconditional etiological and pathogenetic role of the microbial factor in the development of inflammatory periodontal diseases.

The proposed method is tested in the pathology Department, JSC "City clinical hospital №3". CM. Kirov, State budgetary institution of health of the Astrakhan region "Children's city clinical hospital №2" and sbei HPE AGM of the Ministry of health at the Department of therapeutic stomatology of the 100 patients in the period 2012-2014, the patients ' age from 18-60 years of age with diagnoses of chronic catarrhal gingivitis, chronic hypertrophic gingivitis, chronic generalized p�romantic of mild and moderate severity.

When referring patients complained of bleeding gums while brushing teeth, bad taste in mouth and smell, itching gums. Great importance was attached to history, to detect errors of individual hygiene of oral cavity. During the inspection evaluated the state of the mucous membrane of the mouth, cancer alert, bite, checked the indexes of the Communist party of the teeth, simplified oral hygiene index of the oral cavity green - Vermillion (OHI-S), papillare-marginal-alveolar index (PMA) in the modification of Parma, the level of inflammatory and destructive changes in the periodontium, the periodontal index (PI according to Russell, the index bleeding papillae (PBI) (Muhlemann). Inspection of the definition of these indices was carried out in 1, 8 and 40 days of starting treatment. X-ray methods included an orthopantomogram and sighting radiography. Immunological examination included determination of IL-β, IL-4, IL-6, IL-8 in gingival fluid. The study was conducted by the method of enzyme-linked immunosorbent assay, using a commercial enzyme immunoassay kits LLC "Cytokine" (S.-Petersburg), All patients were divided into two groups. In one group (main) used the claimed method of treatment in the other (control) were treated according to the standard scheme: in chronic catarrhal and g�Petrovietnam gingivitis was carried out the removal of dental plaque, with the subsequent complex rinses in 0.05% solution of chlorhexidine digluconate and applications on the affected periodontal tissues "Helical-gel" or "Metrogyl-dent", the film "diplen-dent" with metronidazole. In chronic generalized periodontitis mild and moderate severity, after the removal of dental plaque, made antiseptic gargle with further applying of bandages (gels "Dicloran", "Helical", paste Arrogant") and system vitamin.

The results of examination of patients with periodontal disease before treatment (see tab. No. 1);

The results of examination of patients with periodontal disease on day 8 of treatment (see tab. No. 2);

The results of examination of patients with periodontal diseases 40 day of treatment(see tab. No. 3);

Cytokine levels in the fluid of periodontal pockets of patients with periodontal lesions (PG/ml) (see tab. No. 4);

According to the results, it can be argued, in contrast to the standard scheme, where therapy was able to achieve control over the course of chronic generalized periodontitis mild and moderate severity, then translate the process into a stage of remission, in the main group, the use of gel form "betalain" has achieved the status of intact periodontal disease in most patients.

Thus, the study in�revealed, the decrease of clinical criteria that reflect the ecosystem of the oral cavity, the level of cytokines was observed in both groups at 8 and 40 day. At the same time, the use in the treatment of gel form "betalain" led to a more dynamic change of indices that reflect the state of periodontal tissues and indicators of the ensemble of interleukins. This helped stabilize the process in most patients, to prevent the flowing in aggressive periodontal inflammation due to the reversibility of the inflammatory process. Below are the results of testing.

Clinical example No. 1

Patient B., 27 years. Diagnosis: chronic hypertrophic gingivitis. The diagnosis was made on the basis of clinical examination methods (inspection, assessing the condition of the mucous membrane of the mouth, cancer alert, bite, checked the indexes of the Communist party of the teeth, simplified oral hygiene index of the oral cavity green - Vermillion (OHI-S), papillare-marginal-alveolar index (PMA) in the modification of Parma, the level of inflammatory and destructive changes in the periodontium - with the periodontal index (PI according to Russell, the index bleeding papillae (PBI) (Muhlemarm)),x-ray methods (orthopantomogram, sighting radiography) and immunological examination (determination of IL-1β, IL-4, IL-6, IL-8 in des�eve of liquid).

Treatment was carried out by removal of dental plaque, with subsequent complex rinses in 0.05% solution of chlorhexidine digluconate and applications on the affected periodontal tissues "Metrogyl-dent", the film "diplen-dent" with metronidazole, followed by exposure to a laser semiconductor laser therapy dental therapy device "Optogan with periodontal attachment, mode II, with an exposition of 1 minutes, daily, course of treatment 8 days.

Result: on day 8 of treatment was mild inflammatory process, increased tone of the weakened blood capillaries, which contributed to the reduction of bleeding and regeneration of periodontal tissues. Despite treatment, the content of cytokines in gingival fluid changes slightly, which is associated with preserved inflammation. 40 day follow-up, according to the results obtained, managed to gain control over the disease process and translate into remission.

Clinical example No. 2

Patient B., 35 years. Diagnosis: chronic hypertrophic gingivitis. The diagnosis was made on the basis of clinical examination methods (inspection, assessing the condition of the mucous membrane of the mouth, cancer alert, bite, checked the indexes of the Communist party of the teeth, a simplified index of Gigi�NY oral green-Vermillion (OHI-S), papillare-marginal-alveolar index (PMA) in the modification of Parma, the level of inflammatory and destructive changes in the periodontium - with the periodontal index (PI according to Russell, the index bleeding papillae (PBI) (Muhlemann), x-ray methods (orthopantomogram, sighting radiography) and immunological tests (determination of IL-1β, IL-4, IL-6, IL-8 in gingival fluid).

Treatment was conducted according to the claimed method, namely 1 ml "Geladen" gel mixed on a slide with 0.0005 mg "betalain" dissolved in 1 ml of water for injection, then the contents of the disposable application syringe inflicted on isolated from the saliva of the processed portion of the affected periodontal tissues and left to its full suction for 1 minute followed by exposure to laser therapy using a semiconductor laser dental therapy device "Optogan with periodontal attachment, mode II, with an exposure of 3 minutes, the course of treatment for 8 days on a daily basis.

Result: on day 8 of treatment, the dynamics of the disease has improved, gum health has stabilized, the mucous purchased a pale pink color, interdental gingival papillae pointed, bleeding was stopped. 40 day follow-up, when using gel�howl of the form "betalain", on the basis of the results achieved the status of intact periodontium.

Clinical example No. 3

Patient W., age 31. Diagnosis: chronic hypertrophic gingivitis. The diagnosis was made on the basis of clinical examination methods (inspection, assessing the condition of the mucous membrane of the mouth, cancer alert, bite, checked the indexes of the Communist party of the teeth, simplified oral hygiene index of the oral cavity green - Vermillion (OHI-S), papillare-marginal-alveolar index (PMA) in the modification of Parma, the level of inflammatory and destructive changes in the periodontium - with the periodontal index (PI according to Russell, the index bleeding papillae (PBI) (Muhlemann)), x-ray methods (orthopantomogram, sighting radiography) and immunological examination (determination of IL-1β, IL-4, IL-6, IL-8 in gingival fluid).

Treatment was conducted according to the claimed method, namely 1 ml "Geladen" gel mixed on a slide with 0.0005 mg "betalain" dissolved in 1 ml of water for injection, then the contents of the disposable application syringe inflicted on isolated from the saliva of the processed portion of the affected periodontal tissues and left to its full suction for 3 minutes followed by

the influence of laser therapy with La�semiconductor cluster dental therapy device "Optogan with periodontal attachment, regime II, with an exposure of 5 minutes, the course of treatment for 8 days on a daily basis.

Result: on day 8 of treatment, the dynamics of the disease has improved, gum health has stabilized, the mucous purchased a pale pink color, interdental gingival papillae pointed, bleeding was stopped. 40 day follow-up, when you use the gel form of "betalain", on the basis of the results achieved the status of intact periodontium.

The proposed method achieved: -increased protective-adaptive pathogenetic mechanisms, correcting immune abnormalities in periodontal tissues;

-gel formula "betalain" has high fluidity, so completely fills periodontal pockets or other portion of the mucous membrane of the oral cavity that contributes to prolonged effects on periodontal tissues and the ease of application one-time application syringe;

- acceleration of the timing of regeneration within 3-8 days, depending on the nosological form of the disease;

- quick control over the course of the disease, to achieve a state of intact periodontal disease in most patients; -the influence of laser therapy using a semiconductor laser dental therapy device "Optogan" parodontologically, which are anti-inflammatory, bactericidal and bacteriostatic effect, normalizes microcirculation vessels, reparative processes in tissues and blood rheology;

- the effectiveness of treatment of periodontal disease, can reduce economic costs for medical supervision of the patient in the dental institutions;

- improving the quality of life of the patient in a social society.

The indicators presented in the medians

* the significance of differences with control group p<0,05;

* * significance of differences with control group p<0.01.

A method of treating periodontal disease by local injection of medications and laser, characterized in that 1 ml of Gaudent" gel is mixed on a slide with 0.0005 mg "betalain" dissolved in 1 ml of water for injection, then the contents of the disposable application syringe is applied to isolated from the saliva of the processed portion of the affected periodontal tissues and leave until it is completely absorbed within 1-3 minutes followed by exposure to laser therapy using a semiconductor laser dental therapy device "On�of todan with periodontal attachment, regime II, with an exposition of 3-5 minutes, the course of treatment for 8 days every day.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention represents an agent for treating a pulp inflammation differing by the fact that it contains Bezornil ointment and Dycal ivory paste in ratio 1:1 blended until smooth.

EFFECT: invention provides relieving oedema and pain on the day of doctor's appointment, accelerating the pulp tissue regeneration process, creating the reparative dentin within 30 days, and ensures the higher clinical effectiveness in the pulp inflammations.

2 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: a phytopreparation containing bee wax 1.9 g and a herbal extract 0.1 g with the above herbal extract containing common oak bark, common St. John's wort herb and creeping thyme (Thymus) herb in equal proportions is used.The preparation is used as a chewing substrate (a chewing gum) for two weeks 3 times a day 15 minutes after meals.

EFFECT: using the invention improves clinical manifestations of the disease; oral inflammations are supposed to relieve or reduce; the length of erosion and ulcer epithelisation is reduced; the oral fluid structural properties are normalised by increasing phosphorus and magnesium, reducing protein, calcium and TBA.

1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: vitamins A and E, novocaine blocades of parotid salivary glands, intake of potassium iodide solution, intake of galantamine, additionally administered is "Vezugen" in a dose of 2 tablets (capsules) 2 times per day for 30 days are administered.

EFFECT: invention makes it possible to stimulate the formation of own saliva in patients in case of drug sialoadenopathy, conditioned by chemotherapy of malignant tumours.

2 ex

FIELD: medicine.

SUBSTANCE: 20-25 minutes after surgical intervention, a mouth bath of an implantation area with the Tonsinal phytopreparation diluted in an amount of 2.5 g in 100 ml of boiled water of room temperature is executed. 20-25 minutes later the Plastin CM-1 phytopreparation is applied on the alveolar process mucosa within the implantation area from the vestibular side for 1.5-2 hours. That is preceded by the desalivation of the oral cavity and mouth rinsing carefully with the Tonsinal solution trying to avoid any dynamic movements. The above procedures are performed 3-4 times a day for at least 10 days.

EFFECT: more effective dental implantation by improving microcirculation, fast normalising of oral microbiocoenosis, wound surface healing by immediate union, reliable implant attachment to gums and providing the implant stability.

3 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine, namely to dentistry, and can be used for the treatment of conditions, related with the increased expression of MMP-13, selected from the group, consisting of loss of one or more teeth fixation, teeth loss, teeth mobility, formation of recesses, bone tissue loss and a combination of two and more of the said conditions. For this purpose the application of 4-acetamidophenyl 2-isopropyl-5-methylcyclohexylcarbonate in the production of a medication for the treatment of the said conditions is claimed. A composition for teeth care, containing an orally acceptable carrier and a therapeutically effective quantity of a MMP-13 inhibitor in the form of 4-acetamidophenyl 2-isopropyl-5-methylcyclohexylcarbonate is also claimed.

EFFECT: group of inventions provides the effective treatment of the said conditions die to effective MMP-13 suppression.

3 cl, 5 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: method involves professional oral hygiene is carried out consisting in ultrasonic removal of supra- and subgingival dental deposits and polishing of supragingival teeth. Bite splinting and recovery of dentition integrity may be required. After dissecting a mucoperiosteal flap according to the known technique, an incision area is sanitated by means of a photodynamic therapy (PDT). The PDT is conducted with the use of a diode laser at wave length 660±5 nm and emitting power 0.5-1.0 Wt. The photosensitiser "Photoditasin" in the form of 0.5% gel is introduced by means of a cannula into dental gaps, under the dissected segments of the flap and onto the mucosal tissue for 5 minutes. The photosensitiser is washed out, and the gingival pockets are repeatedly exposed to laser light for 2-3 min in the same environment. Sterile osteoplastic material is introduced into bone defects, and the flap is sutured together.

EFFECT: effective cleansing of the surgical area, eliminating the periodontal inflammation, stimulating tissue osteogenesis and regeneration, stabilising the processes of bone tissue absorption of alveolar interdental septa and preserving the tissues.

2 cl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry, namely to an oral care composition and to a method for increasing the solubility of an active ingredient recovered from magnolia extract - tetrahydrohonokiol. The oral care composition contains an active ingredient recovered from the magnolia extract - tetrahydrohonokiol, propylene glycol and an orally acceptable carrier, in a certain amount.

EFFECT: content of the certain amount of propylene glycol in the oral care composition increases the solubility of tetrahydrohonokiol that leads to improving the effectiveness of its delivery and bioavailability.

3 cl, 8 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine and is intended for oral cavity care. Compositions include a multi-layered film and an orally acceptable carrier. The carrier contains the first flavouring agent, with the second flavour being contained in the present central layer of the multi-layered film, located between two external surface layers. The first and second flavouring agents can be similar or different. Each film layer can include a film-forming polymer, for instance, hydroxypropylmethylcellulose. The external layers can include a substance, modulating the release of the flavouring agent, for instance, polyvinylacetate or hydroxymethylcellulose. The carrier can be a means for teeth cleaning or a liquid for mouth rinsing.

EFFECT: obtaining the composition for oral cavity care.

22 cl, 3 dwg, 4 tbl, 11 ex

FIELD: medicine.

SUBSTANCE: vaseline-lanolin (2:1) based ointment 74.0 g is added with a 40% herbal alcoholate 25 ml of the following composition (in the mixture of a herbal raw material: alcohol base - 1:5), weight fractions: nodding catchfly herb - 3 weight fractions, pot marigold blossom - 1 weight fraction, spiraea herb - 1 weight fraction, with the ointment added with clove oil 1.0 ml. The prepared ointment is applied on inflamed periodontal and oral mucosal tissues for 20 minutes 2-3 times a day for 14 days; the patient is advised not to drink or eat for 1 hour.

EFFECT: method enables increasing clinical effectiveness by combining high antimicrobial, immunomodulatory, anti-allergic and keratoplastic activity and ease of use.

3 ex

FIELD: medicine.

SUBSTANCE: on completion of the antibacterial course, sodium hyaluronate in the form of a gel is single administered by means of a syringe with a needle of 2 cm long or more under an oral mucosa along a transitory fold into the points within projections of apexes of dental roots 1.4, 2.4, 3.6, 4.6 and into a point on the mid-line of projections of apexes of anterior roots of upper and lower jaw respectively. The needle is brought under the mucosa on the lower jaw by transecting the projections of an alveolar counterfort line. On the upper jaw - by transecting the projections of the upper counterfort line. While removing the needle from the mucosa, the syringe content is squeezed out. Sodium hyaluronate is administered into both jaws in an amount of 3.0 to 4.4 ml.

EFFECT: method enables increasing the jaw bone density within counterforts, as well as soft and bone tissues of periodontium.

4 tbl, 16 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: method involves the fasting oral administration of placenta hydrolysate 2ml in water 200 ml at a temperature of 37°C in the morning. After that, the patient is laid down on his/her back and exposed to infrared laser light generated by the laser scanning physiotherapeutic simulator SLSF-03.2 IK. An initial end face output power is 2 mW at a power flow density of 50 mW/cm2 on a projection of an ulcer defect on frame No. 57 or No. 59 with laser light modulation at a frequency of 12-15 a second for 3 minutes per one field. That is followed by exposing a projection of a bend of the elbow on frame No. 30 or No. 40 for 10 minutes per a field. Further, the patient stays in the same position to perform transcranial electric stimulation generated by the Doctor TES-03 apparatus. A gel forehead electrode (+) is applied in the middle of the forehead skin until adhered to the skin uniformly. Two gel postaural electrodes are applied on bony mastoid processes (-) until adhered to the skin uniformly. The electrodes are fixed with a headband. The exposure has a current intensity of 1.5 mA in the form of a bipolar pulsing frequency of 77.5 Hz for 20 minutes. The therapeutic course makes 10 daily procedures.

EFFECT: method provides reducing pain and dyspeptic syndromes, asthenovegetative syndrome, accelerating ulcerous process healing in the mucous membrane, achieving a stable remission, normalising the functional state of the adjacent organs, namely the liver, pancreas, reducing a desire to smoke up to a complete smoking cessation completely for the whole period of treatment.

4 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: first stage involves the antegrade palpation-assisted insertion of a heavy-ended phlebextractor through an incision at the medial malleolus to straighten varicose segments. The phlebextractor is removed thereafter from the incision at the medial malleolus. Tumescence anaesthesia is applied along the vein trunk. That is followed by the coagulation of an inconsistent tibial segment of the great saphenous vein with the use of a laser light guide. The laser light guide is removed from the incision at the medial malleolus. A cosmetic stitch is applied on the wound. At the second stage: the heavy-ended phlebextractor is inserted palpation-assisted in the retrograde direction through a cross-ectomy incision to straighten varicose segments. The heavy-ended phlebextractor is used to remove any inconsistent valves, and an aiming beam controlled laser light guide is delivered along the phlebextractor. Thereafter, the phlebextractor is taken out of the cross-ectomy incision. Tumescence anaesthesia is applied. That is followed by the laser coagulation of an inconsistent femoral segment of the vein. The laser light guide is taken out of the cross-ectomy incision. The great saphenous vein stump is ligatured. The wound is closed. The whole surgical procedure is continuously ultrasound-controlled.

EFFECT: method enables the laser light guide coagulation of the inconsistent segments of the vein causing no paravasal inflammatory reaction, delivering the laser light guide precisely by using the heavy-ended phlebextractor.

11 dwg

FIELD: medicine.

SUBSTANCE: as medications administered are: methotrexate 15 mg per week intake, folic acid 5 mg per week intake, movalis 15 mg per day intake. Laser therapy is administered in differential way depending on degree of disease activity and level of glucosaminoglycanes (GAG). In case of second stage of rheumatoid arthritis - index DAS28 3.2-5.1, level of glucosaminoglycanes 0.510±0.032 g/l, 7 daily procedures of intravenous laser irradiation are carried out. Radiating head KL-VLOK with wavelength 635 nm, power at the end of disposable light guide 1.5 mW, exposure time 15 minutes and laser head KL-VLOK-365 with wavelength 365 nm, power at the end of light guide 1.0 mW, exposure time 5 minutes, are alternated. In case of third degree of activity index DAS28 is higher than 5.1, GAG level is equal or is higher than 0.618±0.069 g/l, 10 procedures are carried out Radiating head KL-VLOK with wavelength 635 nm, power at outlet of disposable light guide 1.5-2.0 mW, exposure time 15 minutes and laser head KL-VLOK-365 nm, power at outlet of disposable light guide 1.0 mW, time of exposure 5 minutes.

EFFECT: method makes it possible to reduce frequency of exacerbations, reduce expression of clinical manifestations, reduce drug load on patient, provides earlier arrest of disease symptoms due to differentiated approach in case of administration of intravenous laser irradiation of blood and its normalising action on GAG indices and reduction of disease activity degree.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine, namely to dermatology and mycology, and can be applied in the treatment of skin and its appendages. A pharmaceutical composition for external application contains nanoparticles for the laser thermotherapy of infectious affections of the skin and its appendages. The nanoparticles are characterised by, at least, one localised surface Plasmon resonance in the range of a wavelength from 400 to 1100 nm. The nanoparticles are dispersed in a physiologically acceptable carrier, which is characterised by the absence of the absorption or weak absorption and/or weak dispersion of light radiation in the said range of wavelengths and possessing biocidal properties. The pharmaceutical composition is applied on an affected area and irradiated by laser radiation with a wavelength close to the wavelength of the localised surface Plasmon resonance of the nanoparticles, contained in the composition, or equal to it. The irradiation is continued until the desirable temperature of heating of the said area is achieved.

EFFECT: group of inventions ensures an increased treatment efficiency, reduction of a risk of development of side effects, reduction of the number of recurrences due to the application of the pharmaceutical composition, capable of absorbing energy of the light radiation and transforming it into heat energy with the achievement of the specified temperature with laser irradiation at the specified wavelength with the lower intensity of laser radiation and possessing biocidal properties.

63 cl, 3 dwg, 1 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: nucleus of lens is fragmented completely by femtosecond laser light at power 7,000-8,500 nJ; that is followed by making a corneal flap incision, dilating the pupil mechanically, and separating the synechias. A continuous circular capsulorhexis is performed, and the fragmented crystalline substance is emulsified. If observing degree II nuclear density, the nucleus is fragmented on 8 segments, while degrees III and IV requires fragmenting the nucleus on 8 segments in a combination with the circular incision in the centre 3 mm in diameter.

EFFECT: method provides creating the optimum conditions for phakoemulsification of the crystalline lens in the narrow rigid pupil and iris-lens synechias for enabling the adequate fixation of the IOL in the capsular sac with reducing intraoperative injuries and preventing the complications.

3 cl, 3 ex

FIELD: medicine.

SUBSTANCE: method involves performing a vitrectomy with removing a posterior hyaloids of a vitreous body, and a laser retinal endocoagulation at wave length 532 nm, emitting power 120-200 mWt, pulse length 0.1-0.2 s, spot diameter 150-200 mcm. A chorioretinal venous anastomosis (CRVA) is induced by exposing the branches of the central vein of the retina to the third-order laser light at wave length 532 nm in a number of 4 coagulated, emitting power 500 mWt, pulse length 1 sec and spot diameter 50 mcm. The vitrectomy is preceded by the intramuscular injections of 12.5% etamylate 4ml and the intravenous administration of 0.5% tranexamic acid 1 g 25-30 minutes before. That is followed by the droplet intravenous administration of an infusion solution containing 0.1% perlinganit 10 ml in 0.9% normal saline 100 ml at an initial rate of 5 mcg/min. The area to be exposed to laser is specified at least in 3 diameters of the disk from the optic disk. The third-order laser applications are applied on the branches of the central vein of the retina in a number from 2 to 4 at wave length 532 nm, emitting power 300-400 mWt, exposure 0.5 s, spot diameter 500 mcm in two points in the proximal and distal direction from the CRVA induction point. Immediately before the CRVA induction, a salt-water infusion flow is increased until the central retinal artery starts pulsating. The surgical management is completed by plugging the vitreal cavity with 20% air-gas mixture SF6.

EFFECT: effective management of the clinical course of the retinal venous thrombosis by considerable reduction of postoperative haemophthalmias.

2 ex

FIELD: medicine.

SUBSTANCE: method involves professional oral hygiene is carried out consisting in ultrasonic removal of supra- and subgingival dental deposits and polishing of supragingival teeth. Bite splinting and recovery of dentition integrity may be required. After dissecting a mucoperiosteal flap according to the known technique, an incision area is sanitated by means of a photodynamic therapy (PDT). The PDT is conducted with the use of a diode laser at wave length 660±5 nm and emitting power 0.5-1.0 Wt. The photosensitiser "Photoditasin" in the form of 0.5% gel is introduced by means of a cannula into dental gaps, under the dissected segments of the flap and onto the mucosal tissue for 5 minutes. The photosensitiser is washed out, and the gingival pockets are repeatedly exposed to laser light for 2-3 min in the same environment. Sterile osteoplastic material is introduced into bone defects, and the flap is sutured together.

EFFECT: effective cleansing of the surgical area, eliminating the periodontal inflammation, stimulating tissue osteogenesis and regeneration, stabilising the processes of bone tissue absorption of alveolar interdental septa and preserving the tissues.

2 cl, 1 ex

FIELD: veterinary medicine.

SUBSTANCE: in down-calving cows the entire mammary gland is irradiated with the contact method with scanning using laser beam with a wavelength of 0.63 microns. The low-intensity laser emitter power is 30 mW. The procedure is carried out for five minutes and is repeated five times with an interval of 48 hours.

EFFECT: method enables to increase the effectiveness of prevention of mastitis by increasing the overall and the local resistance of the cow organism prior to calving, increase in the activity of antioxidant defence of the organism, reduction of toxic load to its organism.

3 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to physiotherapy, dermatology and cosmetology, and can be used in stimulating regenerative processes in the face and/or neck skin. That is ensured by performing three stages, first two of which involve preparing to the third one. The first stage involves blood sampling from the patient, recovering the blood plasma, and enriching it with thrombocytes; the purified and enriched plasma is administered intradermally under the skin. Two days later, the second stage follows that involves the subcutaneous injections of hyaluronic acid. The third stage is performed 2-3 days later to expose different skin layers to laser light passing through different face and/or neck sections two to five times for one procedure. Passing once involves the alternating short-wave and long-wave laser exposure at a wave length of 1564-2940 nm. The procedure is repeated every 3-5 days with an increasing laser beam pulse energy from 35 mJ to 65 mJ.

EFFECT: method provides the safe effective stimulation of the regenerative processes in the face and/or neck skin ensured by the complex exposure covering different layers of derma and epidermis and involving different regeneration links.

2 ex

FIELD: medicine.

SUBSTANCE: introduction of a photosensitiser and exposure to low intensive laser irradiation are realised. After carrying out photodynamic therapy (PDT) spectral-fluorescent diagnostics is performed and a degree of the medication burning out is determined. If the ratio of the tumour/norm is higher than 1.0, the absence of burning out is diagnosed. If the ratio of the tumour/norm is 0.8-1.0, partial burning out is diagnosed. If the ratio of the tumour/norm is lower than 0.8, complete burning out is diagnosed. In case of partial burning out or the absence of burning out PDT procedure is continued additionally with the power density of 0.35 W/cm2 by a step-by-step supply of 50 J/cm2 with the evaluation of a degree of burning out after each step. When complete burning out is registered, PDT procedure is finished.

EFFECT: increased efficiency of the photodynamic therapy due to objective monitoring of the performed treatment, selection of individual doses of the laser influence on the basis of fluorescence parameters, which makes it possible to obtain the full response of the tumour to the treatment and reduce side effects and the number of recurrences.

4 ex

FIELD: medicine.

SUBSTANCE: invention aims at treating drug-induced dry eye syndrome (DI-DES). Treating DI-DES implies taking the past medical history, measuring tear production and eye xerosis values reduced and increased respectively in relation to the norm. Unpreserved ocular hypotensive medications are prescribed in the patient. Unpreserved artificial tears are also applied. The lachrymal fluid is analysed by a multicytokine technique. If the analysis shows increased concentrations of proinflammatory cytokines - interleukin-6, interleukin-8, interleukin-12, Th-1 - interleukin-2, interferon-gamma, and Th-2 - interleukin-4, by min 30% in relation to the patient's age norm, a chronic immune ocular inflammation is detected. That requires transpalpebral Blepharogel-1 phonophoresis and 1% hydrocortisone ointment phonophoresis on the sub-mastoidal region from both sides; the therapeutic course is 8-10 daily procedures.

EFFECT: optimal conditions for diagnosing and reasoned differentiated therapy of DI-DES that enables prescribing the pathogenetically reasoned therapy in due time and increasing the efficacy of the therapeutic exposure.

1 tbl, 2 ex

Up!